Organization, Plan of Business Operations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | ||
|---|---|---|---|
Nov. 12, 2018 |
Sep. 30, 2018 |
Dec. 31, 2017 |
|
| Retained Earnings (Accumulated Deficit) | $ (38,290) | $ (20,661) | |
| Subsequent Event [Member] | Line of Credit [Member] | |||
| Initial Financing Amount | $ 3,000 | ||
| Interim Financing Amount | 7,000 | ||
| Subsequent Event [Member] | Second Closing [Member] | |||
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | 180,000 | ||
| Subsequent Event [Member] | InvaGen Pharmaceuticals Inc [Member] | |||
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 35,000 | ||
| Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 5,833,333 | ||
| Business Acquisition, Share Price | $ 6.00 |
| X | ||||||||||
- Definition Amount of initial financing receivable. No definition available.
|
| X | ||||||||||
- Definition Amount of interim financing receivable. No definition available.
|
| X | ||||||||||
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of equity interests issued or issuable to acquire entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. No definition available.
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|